Autolus Therapeutics PLC ADR AUTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
-
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
-
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
-
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
-
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Trading Information
- Previous Close Price
- $1.72
- Day Range
- $1.59–1.74
- 52-Week Range
- $1.18–2.58
- Bid/Ask
- $1.60 / $1.75
- Shares Outstanding
- 266.16M
- Market Cap
- $425.86M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 752
- Website
- https://www.autolus.com
Valuation
|
Metric
|
AUTL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.70 |
Price/Sales | 3.63 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AUTL
|
|---|---|
Quick Ratio | 4.06 |
Current Ratio | 4.89 |
Interest Coverage | −5.97 |
Quick Ratio
AUTL
Profitability
|
Metric
|
AUTL
|
|---|---|
Return on Assets (Normalized) | −42.53% |
Return on Equity (Normalized) | −130.78% |
Return on Invested Capital (Normalized) | −86.69% |
Return on Assets
AUTL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|T&&&%% | LOCK|&&#f | $127B | |||
| Moderna Inc
MRNA
| LOCK|bYZ&jg | LOCK|JpN | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%NBdgN@ | LOCK|c&?Dy | $81B | |||
| argenx SE ADR
ARGX
| LOCK|HL>&$#% | LOCK|@L | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|N%STCK@ | LOCK|j?% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>lkB^m | LOCK|@?z! | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|W$h!z#% | LOCK|>^B#r | $27B | |||
| Incyte Corp
INCY
| LOCK|@$C&<Y | LOCK|@qc | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|bYrmPJz | LOCK|@DC | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|@kxf$x | LOCK|>y | $14B |
United States